CLDX · Intrinsic value
Is Celldex Therapeutics, Inc. (CLDX) overvalued or undervalued?
TickerWorth's dcf fair value for Celldex Therapeutics, Inc. (CLDX) is $6.96 a share, against the delayed market price of $27.97 (302% above fair value), as of Oct 19, 2026. no growth rate up to 300%/yr justifies the price under these economics It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is CLDX overvalued?
- DCF fair value
- $6.96
- Market price
- $27.97
- Downside to fair value
- 75.1%
- Verdict
- 302% above fair value
Reverse DCF, on our cash-flow model rather than the fair value above: no growth rate up to 300%/yr justifies the price under these economics
What is CLDX's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: profitability is weak.
- Value · 38 of 100
Cheaper than 38% of Healthcare companies in US
- Price vs worth · — of 100
- Quality · 9 of 100
More profitable than 9% of Healthcare companies in US
- Financial health · 80 of 100
Financially stronger than 80% of Healthcare companies in US
- Growth · 0 of 100
Growing faster than almost none of the Healthcare companies in US
- Momentum · 37 of 100
Outperformed 37% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
CLDX DCF valuation: what the price assumes
At a recent price of $27.96, Celldex Therapeutics, Inc. (CLDX) trades 302% above TickerWorth's base-case discounted-cash-flow (DCF) fair value of $6.96 per share — meaning the market currently prices CLDX overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -75.1% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
The valuation discounts Celldex Therapeutics, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 9.4%, with a long-run terminal growth rate of 2.5%. About 63% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, CLDX's modeled DCF value ranges from about $6.01 to $7.42 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Celldex Therapeutics, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of CLDX's intrinsic value. Figures update as new filings and prices come in.
Every input behind CLDX's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $160,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 2.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | -10% → -6% → -3% → 0% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.90 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 79M |
| Market priceBackup price feed · as of 2026-10-19 13:53 UTC | $27.96 |
Change CLDX's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Celldex Therapeutics, Inc. do?
What does it do?
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 198 people.
How does it make money?
The business turns $158,000 in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -366468.2%), after a 0% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.7× equity), comfortably covers its short-term bills (11.8× current ratio), and is currently lossmaking.
Who at CLDX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Martin Samuel Bates | SVP AND CFO | Option exercise | $50,000.46 | Form 4 for Martin Samuel Bates (opens sec.gov in a new tab) | |
| PEPIN RONALD | SR. VP & CBO | Option exercise | $75,134.49 | Form 4 for PEPIN RONALD (opens sec.gov in a new tab) | |
| PEPIN RONALD | SR. VP & CBO | Option exercise | $30,580.00 | Form 4 for PEPIN RONALD (opens sec.gov in a new tab) | |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | Open-market sale | $121,209.77 | Form 4 for Jimenez Freddy A. (opens sec.gov in a new tab) | |
| Wright Richard M. | — | Option exercise | $61,997.45 | Form 4 for Wright Richard M. (opens sec.gov in a new tab) | |
| Wright Richard M. | — | Option exercise | $276,855.36 | Form 4 for Wright Richard M. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is CLDX's intrinsic value?
TickerWorth's base-case DCF fair value for Celldex Therapeutics, Inc. (CLDX) is $6.96 per share, versus a market price of $27.96 (302% above fair value).
Is CLDX overvalued or undervalued?
On our DCF model CLDX looks overvalued vs fair value at $27.96. This is an educational estimate, not advice.
What discount rate is used for CLDX?
A WACC of 9.4% and a terminal growth rate of 2.5%.
Is Celldex Therapeutics stock undervalued?
TickerWorth's dcf fair value for Celldex Therapeutics, Inc. (CLDX) is $6.96 against a market price of $27.97. Our read: 302% above fair value. This is a model estimate, not investment advice.
Celldex Therapeutics (CLDX) DCF valuation and fair value
Our dcf fair value for Celldex Therapeutics, Inc. (CLDX) is $6.96, built on a 9.4% discount rate (WACC) and 2.5% terminal growth. Every assumption is listed on this page with its source.
What growth is priced into Celldex Therapeutics stock?
no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $27.97. A model estimate, not investment advice.
Celldex Therapeutics (CLDX) insider trading
The most recent insider filing (SEC Form 4) for Celldex Therapeutics, Inc. (CLDX): Martin Samuel Bates, SVP AND CFO, option exercise on 2026-01-02. The latest filings are listed on this page. A disclosure, not a signal to trade.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.